Steven J. Fliesler
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Steven J. Fliesler has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
Michael J. Richards
§§the Department of Ophthalmology (Saint Louis University Eye Institute), Saint Louis University School of Medicine, St. Louis, MO 63104
6 shared publicationsNeal S. Peachey
Cleveland VA Medical Center, and Cole Eye Institute, Cleveland Clinic Foundation, Cleveland, OH, USA
3 shared publicationsBarbara A. Nagel
Departments of Ophthalmology and Pharmacological & Physiological Science, Saint Louis University School of Medicine, St Louis, MO, USA
2 shared publicationsDana K. Vaughan
Department of Biology, University of Wisconsin Oshkosh, Oshkosh, WI, USA
2 shared publicationsRichard S. Brush
§the Department of Ophthalmology, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104
2 shared publicationsRobert E. Anderson
§the Department of Ophthalmology, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104
2 shared publications
Latest Publications
- Open Access
- 1 July 2008
- Published by Elsevier in Journal of Lipid Research
- Vol. 49 (7) , 1488-1499
Alteration of retinal rod outer segment membrane fluidity in a rat model of Smith-Lemli-Opitz syndrome
- 1 July 2008
- Published by Elsevier in Journal of Lipid Research
- Vol. 49 (7) , 1488-1499
Open AccessAlteration of retinal rod outer segment membrane fluidity in a rat model of Smith-Lemli-Opitz syndrome
- Open Access
- 21 December 2007
- Published by Wiley in Journal of Neurochemistry
- Vol. 105 (3) , 1032-1047
Lipidomic analysis of the retina in a rat model of Smith–Lemli–Opitz syndrome: alterations in docosahexaenoic acid content of phospholipid molecular species
Smith–Lemli–Opitz syndrome (SLOS) is a complex hereditary disease caused by an enzymatic defect in the last step of cholesterol biosynthesis. Progressive retinal degeneration occurs in an AY9944-induced rat model of SLOS, with biochemical and electroretinographic hallmarks comparable with the human disease. We evaluated alterations in the non-sterol lipid components of the retina in this model, compared with age-matched controls, using lipidomic analysis. The levels of 16:0–22:6 and 18:0–22:6 phosphatidylcholine molecular species in retinas were less by > 50% and > 33%, respectively, in rats treated for either 2 or 3 months with AY9944. Relative to controls, AY9944 treatment resulted in > 60% less di-22:6 and > 15% less 18:0–22:6 phosphatidylethanolamine molecular species. The predominant phosphatidylserine (PS) molecular species in control retinas were 18:0–22:6 and di-22:6; notably, AY9944 treatment resulted in > 80% less di-22:6 PS, relative to controls. Remarkably, these changes occurred in the absence of n3 fatty acid deficiency in plasma or liver. Thus, the retinal lipidome is globally altered in the SLOS rat model, relative to control rats, with the most profound changes being less phosphatidylcholine, phosphatidylethanolamine, and PS molecular species containing docosahexaenoic acid (22:6). These findings suggest that SLOS may involve additional metabolic compromise beyond the primary enzymatic defect in the cholesterol pathway.
- 21 December 2007
- Published by Wiley in Journal of Neurochemistry
- Vol. 105 (3) , 1032-1047
Open AccessLipidomic analysis of the retina in a rat model of Smith–Lemli–Opitz syndrome: alterations in docosahexaenoic acid content of phospholipid molecular species
Smith–Lemli–Opitz syndrome (SLOS) is a complex hereditary disease caused by an enzymatic defect in the last step of cholesterol biosynthesis. Progressive retinal degeneration occurs in an AY9944-induced rat model of SLOS, with biochemical and electroretinographic hallmarks comparable with the human disease. We evaluated alterations in the non-sterol lipid components of the retina in this model, compared with age-matched controls, using lipidomic analysis. The levels of 16:0–22:6 and 18:0–22:6 phosphatidylcholine molecular species in retinas were less by > 50% and > 33%, respectively, in rats treated for either 2 or 3 months with AY9944. Relative to controls, AY9944 treatment resulted in > 60% less di-22:6 and > 15% less 18:0–22:6 phosphatidylethanolamine molecular species. The predominant phosphatidylserine (PS) molecular species in control retinas were 18:0–22:6 and di-22:6; notably, AY9944 treatment resulted in > 80% less di-22:6 PS, relative to controls. Remarkably, these changes occurred in the absence of n3 fatty acid deficiency in plasma or liver. Thus, the retinal lipidome is globally altered in the SLOS rat model, relative to control rats, with the most profound changes being less phosphatidylcholine, phosphatidylethanolamine, and PS molecular species containing docosahexaenoic acid (22:6). These findings suggest that SLOS may involve additional metabolic compromise beyond the primary enzymatic defect in the cholesterol pathway.
- Open Access
- 1 March 2007
- Published by Springer Nature in Pediatric Research
- Vol. 61 (3) , 273-278
Partial Rescue of Retinal Function and Sterol Steady-State in a Rat Model of Smith-Lemli-Opitz Syndrome
- 1 March 2007
- Published by Springer Nature in Pediatric Research
- Vol. 61 (3) , 273-278
Open AccessPartial Rescue of Retinal Function and Sterol Steady-State in a Rat Model of Smith-Lemli-Opitz Syndrome
- 19 December 2005
- Published by Elsevier in Experimental Eye Research
- Vol. 82 (3) , 496-504
Light-induced exacerbation of retinal degeneration in a rat model of Smith–Lemli–Opitz syndrome
- 19 December 2005
- Published by Elsevier in Experimental Eye Research
- Vol. 82 (3) , 496-504
Light-induced exacerbation of retinal degeneration in a rat model of Smith–Lemli–Opitz syndrome
- 31 October 2005
- Published by Elsevier in Experimental Eye Research
- Vol. 81 (4) , 365
Focus on Molecules
- 31 October 2005
- Published by Elsevier in Experimental Eye Research
- Vol. 81 (4) , 365
Focus on Molecules
- 30 September 2005
- Published by Elsevier in Experimental Eye Research
- Vol. 82 (3) , 538-541
Lipid hydroperoxide formation in the retina: correlation with retinal degeneration and light damage in a rat model of Smith–Lemli–Opitz syndrome
- 30 September 2005
- Published by Elsevier in Experimental Eye Research
- Vol. 82 (3) , 538-541
Lipid hydroperoxide formation in the retina: correlation with retinal degeneration and light damage in a rat model of Smith–Lemli–Opitz syndrome
- Open Access
- 1 August 2004
- Published by American Medical Association (AMA) in Archives of Ophthalmology (1950)
- Vol. 122 (8) , 1190-1200
Retinal Degeneration in a Rodent Model of Smith-Lemli-Opitz Syndrome
Smith-Lemli-Opitz syndrome (SLOS) (Online Mendelian Inheritance in Man[OMIM] 270400)1 is the first described exampleof a "multiple congenital anomalies syndrome" and the first in a growing listof human hereditary diseases involving inborn errors of cholesterol biosynthesis.2-4 This often lethal, autosomalrecessive disease affects an estimated 1 in 20 000 to 1 in 60 000primarily white live births worldwide, although the incidence may be as highas 1 in 1590 to 1 in 13 500 (see Battaile et al5),arguably making it the fourth most prevalent autosomal recessive human diseaseknown. The key biochemical features associated with SLOS are abnormal (typicallygrossly elevated) levels of 7-dehydrocholesterol (7DHC), a penultimate precursorof cholesterol, and markedly reduced levels of cholesterol in blood and otherbodily tissues.6-9 Thisabnormality in sterol composition is a consequence of defective activity inthe enzyme 3β-hydroxysterol-Δ7-reductase (EC 1.3.1.21),which catalyzes the conversion of 7DHC to cholesterol.10-12 Theenzymatic defect, in turn, can be ascribed to any one of a myriad of mutationsfound to be associated with the DHCR7 gene (localizedto 11q12-q13), which encodes the Δ7-reductase enzyme.13-15 Patients with SLOSexhibit a constellation of profound phenotypic and functional abnormalities,including microcephaly, holoprosencephaly, dysmorphic craniofacial features,micrognathia, limb asymmetries, syndactyly of the second and third toes, polydactyly,ambiguous genitalia, hypospadias, cleft palate, short nose with antevertednostrils, abnormal visceral development (especially the kidneys, liver, andlungs), hypotonia, failure to thrive, and mental retardation.1-4
- 1 August 2004
- Published by American Medical Association (AMA) in Archives of Ophthalmology (1950)
- Vol. 122 (8) , 1190-1200
Open AccessRetinal Degeneration in a Rodent Model of Smith-Lemli-Opitz Syndrome
Smith-Lemli-Opitz syndrome (SLOS) (Online Mendelian Inheritance in Man[OMIM] 270400)1 is the first described exampleof a "multiple congenital anomalies syndrome" and the first in a growing listof human hereditary diseases involving inborn errors of cholesterol biosynthesis.2-4 This often lethal, autosomalrecessive disease affects an estimated 1 in 20 000 to 1 in 60 000primarily white live births worldwide, although the incidence may be as highas 1 in 1590 to 1 in 13 500 (see Battaile et al5),arguably making it the fourth most prevalent autosomal recessive human diseaseknown. The key biochemical features associated with SLOS are abnormal (typicallygrossly elevated) levels of 7-dehydrocholesterol (7DHC), a penultimate precursorof cholesterol, and markedly reduced levels of cholesterol in blood and otherbodily tissues.6-9 Thisabnormality in sterol composition is a consequence of defective activity inthe enzyme 3β-hydroxysterol-Δ7-reductase (EC 1.3.1.21),which catalyzes the conversion of 7DHC to cholesterol.10-12 Theenzymatic defect, in turn, can be ascribed to any one of a myriad of mutationsfound to be associated with the DHCR7 gene (localizedto 11q12-q13), which encodes the Δ7-reductase enzyme.13-15 Patients with SLOSexhibit a constellation of profound phenotypic and functional abnormalities,including microcephaly, holoprosencephaly, dysmorphic craniofacial features,micrognathia, limb asymmetries, syndactyly of the second and third toes, polydactyly,ambiguous genitalia, hypospadias, cleft palate, short nose with antevertednostrils, abnormal visceral development (especially the kidneys, liver, andlungs), hypotonia, failure to thrive, and mental retardation.1-4
- Open Access
- 1 February 2004
- Published by Elsevier in Journal of Lipid Research
- Vol. 45 (2) , 347-355
Formation of 7-dehydrocholesterol-containing membrane rafts in vitro and in vivo, with relevance to the Smith-Lemli-Opitz syndrome
- 1 February 2004
- Published by Elsevier in Journal of Lipid Research
- Vol. 45 (2) , 347-355
Open AccessFormation of 7-dehydrocholesterol-containing membrane rafts in vitro and in vivo, with relevance to the Smith-Lemli-Opitz syndrome
- 1 May 2000
- Published by Springer Nature in Neurochemical Research
- Vol. 25 (5) , 685-694
Retinal Structure and Function in an Animal Model that Replicates the Biochemical Hallmarks of Desmosterolosis
Desmosterolosis is a rare, autosomal recessive, human disease characterized by multiple congenital anomalies in conjunction with grossly elevated levels of desmosterol and markedly reduced levels of...
- 1 May 2000
- Published by Springer Nature in Neurochemical Research
- Vol. 25 (5) , 685-694
Retinal Structure and Function in an Animal Model that Replicates the Biochemical Hallmarks of Desmosterolosis
Desmosterolosis is a rare, autosomal recessive, human disease characterized by multiple congenital anomalies in conjunction with grossly elevated levels of desmosterol and markedly reduced levels of...
Cholesterol synthesis in the vertebrate retina: Effects of U18666A on rat retinal structure, photoreceptor membrane assembly, and sterol metabolism and composition
Treatment of neonatal rats with U18666A, an inhibitor of desmosterol Δ24-reductase, results in accumulation of desmosterol (Δ5,24) and depletion of cholesterol (Δ5) in various bodily tissues and also causes cataracts. We evaluated the effects of U18666A on the sterol composition, de novo sterol synthesis, and histological structure of the retina. Neonatal Sprague-Dawley rats were injected subcutaneously with U18666A (15 mg/kg, in olive oil) every other day from birth through 3 wk of age; in parallel, control rats received olive oil alone. At 21 d, treated and control groups each were subdivided into two groups: one group of each was injected intravitreally with [3H]acetate; retinas were removed 20 h later and non-saponifiable lipids (NSL) were analyzed by radio-high-performance liquid chromatography. The other group was injected intravitreally with [3H]leucine; 4 d later, one eye of each animal was evaluated by light and electron microscopy and light microscopic autoradiography, while contralateral retinas and rod outer segment (ROS) membranes prepared thereform were analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis/fluorography. In the treated group, the Δ5/Δ5,24 mole ratio of retinas was ca. 1.0, and >88% of the NSL radioactivity was in Δ5,24; in contrast, control retinas had Δ5/Δ5,24 >170, with >80% of the NSL radioactivity in Δ5. Retinal histology, ultrastructure, ROS renewal rates, and rhodopsin synthesis and intracellular trafficking were comparable in both treated and control animals. These results suggest that desmosterol can either substitute functionally for cholesterol in the retina or it can complement subthreshold levels of cholesterol by sterol synergism.
Cholesterol synthesis in the vertebrate retina: Effects of U18666A on rat retinal structure, photoreceptor membrane assembly, and sterol metabolism and composition
Treatment of neonatal rats with U18666A, an inhibitor of desmosterol Δ24-reductase, results in accumulation of desmosterol (Δ5,24) and depletion of cholesterol (Δ5) in various bodily tissues and also causes cataracts. We evaluated the effects of U18666A on the sterol composition, de novo sterol synthesis, and histological structure of the retina. Neonatal Sprague-Dawley rats were injected subcutaneously with U18666A (15 mg/kg, in olive oil) every other day from birth through 3 wk of age; in parallel, control rats received olive oil alone. At 21 d, treated and control groups each were subdivided into two groups: one group of each was injected intravitreally with [3H]acetate; retinas were removed 20 h later and non-saponifiable lipids (NSL) were analyzed by radio-high-performance liquid chromatography. The other group was injected intravitreally with [3H]leucine; 4 d later, one eye of each animal was evaluated by light and electron microscopy and light microscopic autoradiography, while contralateral retinas and rod outer segment (ROS) membranes prepared thereform were analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis/fluorography. In the treated group, the Δ5/Δ5,24 mole ratio of retinas was ca. 1.0, and >88% of the NSL radioactivity was in Δ5,24; in contrast, control retinas had Δ5/Δ5,24 >170, with >80% of the NSL radioactivity in Δ5. Retinal histology, ultrastructure, ROS renewal rates, and rhodopsin synthesis and intracellular trafficking were comparable in both treated and control animals. These results suggest that desmosterol can either substitute functionally for cholesterol in the retina or it can complement subthreshold levels of cholesterol by sterol synergism.